Sign up to save your podcasts
Or
Share How to Treat Early Stage Non-Small Cell Lung Cancer in 2025
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
How to Treat Early Stage Non-Small Cell Lung Cancer in 2025
In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain are joined by Dr. Deepa Rangachari, a thoracic medical oncologist and fellowship program director at Beth Israel Deaconess Medical Center. Together, they dived deep into the treatment algorithms for early-stage non-small cell lung cancer (NSCLC) with a focus on curative intent.
Key topics discussed include:
• The importance of staging and lymph node evaluation in treatment planning.
• The role of neoadjuvant chemoimmunotherapy and the impact of recent trial data, including the CHECKMATE 816 trial.
• The significance of actionable mutations and the use of targeted therapies like Osimertinib and Alectinib.
• The evolving role of ctDNA in treatment decisions and monitoring.
• Insights into the management of side effects associated with Osimertinib and Alectinib.
• The standard of care for unresectable stage 3 NSCLC, including concurrent chemoradiation and the use of Durvalumab.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Join us for an informative discussion that highlights the latest advancements in lung cancer treatment and the importance of personalized care. Don't forget to check out our other episodes in the lung cancer treatment algorithm series!
View all episodes
By Oncology Brothers
4.8
4040 ratings
In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain are joined by Dr. Deepa Rangachari, a thoracic medical oncologist and fellowship program director at Beth Israel Deaconess Medical Center. Together, they dived deep into the treatment algorithms for early-stage non-small cell lung cancer (NSCLC) with a focus on curative intent.
Key topics discussed include:
• The importance of staging and lymph node evaluation in treatment planning.
• The role of neoadjuvant chemoimmunotherapy and the impact of recent trial data, including the CHECKMATE 816 trial.
• The significance of actionable mutations and the use of targeted therapies like Osimertinib and Alectinib.
• The evolving role of ctDNA in treatment decisions and monitoring.
• Insights into the management of side effects associated with Osimertinib and Alectinib.
• The standard of care for unresectable stage 3 NSCLC, including concurrent chemoradiation and the use of Durvalumab.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Join us for an informative discussion that highlights the latest advancements in lung cancer treatment and the importance of personalized care. Don't forget to check out our other episodes in the lung cancer treatment algorithm series!
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
323 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
121 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
294 Listeners
White Coat Investor Podcast
2,439 Listeners
The Curbsiders Internal Medicine Podcast
3,361 Listeners
Core IM | Internal Medicine Podcast
1,145 Listeners
The ONS Podcast
205 Listeners
OncoPharm
187 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
22 Listeners
Becker’s Healthcare Podcast
192 Listeners
Oncology Today with Dr Neil Love
59 Listeners
Two Onc Docs
193 Listeners